Cargando…
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852926/ https://www.ncbi.nlm.nih.gov/pubmed/33526607 http://dx.doi.org/10.1136/jitc-2020-001580 |
_version_ | 1783645888079462400 |
---|---|
author | Birdi, Harsimrat Kaur Jirovec, Anna Cortés-Kaplan, Serena Werier, Joel Nessim, Carolyn Diallo, Jean-Simon Ardolino, Michele |
author_facet | Birdi, Harsimrat Kaur Jirovec, Anna Cortés-Kaplan, Serena Werier, Joel Nessim, Carolyn Diallo, Jean-Simon Ardolino, Michele |
author_sort | Birdi, Harsimrat Kaur |
collection | PubMed |
description | Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades and, although effective in early disease (stages I–II), in later stages, where metastatic tumors are present, these treatments are less effective. Given the spectacular results obtained by cancer immunotherapy in a variety of solid cancers and leukemias, there is now a great interest in appliying this new realm of therapy for sarcomas. The widespread use of immunotherapy for sarcoma relies on immuno-profiling of subtypes, immunomonitoring for prognosis, preclinical studies and insight into the safety profile of these novel therapies. Herein, we discuss preclinical and clinical data highlighting how immunotherapy is being used in soft tissue sarcoma and bone sarcomas. |
format | Online Article Text |
id | pubmed-7852926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-78529262021-02-02 Immunotherapy for sarcomas: new frontiers and unveiled opportunities Birdi, Harsimrat Kaur Jirovec, Anna Cortés-Kaplan, Serena Werier, Joel Nessim, Carolyn Diallo, Jean-Simon Ardolino, Michele J Immunother Cancer Review Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades and, although effective in early disease (stages I–II), in later stages, where metastatic tumors are present, these treatments are less effective. Given the spectacular results obtained by cancer immunotherapy in a variety of solid cancers and leukemias, there is now a great interest in appliying this new realm of therapy for sarcomas. The widespread use of immunotherapy for sarcoma relies on immuno-profiling of subtypes, immunomonitoring for prognosis, preclinical studies and insight into the safety profile of these novel therapies. Herein, we discuss preclinical and clinical data highlighting how immunotherapy is being used in soft tissue sarcoma and bone sarcomas. BMJ Publishing Group 2021-02-01 /pmc/articles/PMC7852926/ /pubmed/33526607 http://dx.doi.org/10.1136/jitc-2020-001580 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Birdi, Harsimrat Kaur Jirovec, Anna Cortés-Kaplan, Serena Werier, Joel Nessim, Carolyn Diallo, Jean-Simon Ardolino, Michele Immunotherapy for sarcomas: new frontiers and unveiled opportunities |
title | Immunotherapy for sarcomas: new frontiers and unveiled opportunities |
title_full | Immunotherapy for sarcomas: new frontiers and unveiled opportunities |
title_fullStr | Immunotherapy for sarcomas: new frontiers and unveiled opportunities |
title_full_unstemmed | Immunotherapy for sarcomas: new frontiers and unveiled opportunities |
title_short | Immunotherapy for sarcomas: new frontiers and unveiled opportunities |
title_sort | immunotherapy for sarcomas: new frontiers and unveiled opportunities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852926/ https://www.ncbi.nlm.nih.gov/pubmed/33526607 http://dx.doi.org/10.1136/jitc-2020-001580 |
work_keys_str_mv | AT birdiharsimratkaur immunotherapyforsarcomasnewfrontiersandunveiledopportunities AT jirovecanna immunotherapyforsarcomasnewfrontiersandunveiledopportunities AT corteskaplanserena immunotherapyforsarcomasnewfrontiersandunveiledopportunities AT werierjoel immunotherapyforsarcomasnewfrontiersandunveiledopportunities AT nessimcarolyn immunotherapyforsarcomasnewfrontiersandunveiledopportunities AT diallojeansimon immunotherapyforsarcomasnewfrontiersandunveiledopportunities AT ardolinomichele immunotherapyforsarcomasnewfrontiersandunveiledopportunities |